KalVista Pharmaceuticals Inc [KALV] stock is trading at $10.35, up 3.19%. An important factor to consider is whether the stock is rising or falling in short-term value. The KALV shares have gain 6.05% over the last week, with a monthly amount glided 18.29%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
KalVista Pharmaceuticals Inc [NASDAQ: KALV] stock has seen the most recent analyst activity on January 31, 2025, when JMP Securities initiated its Mkt Outperform rating and assigned the stock a price target of $19. Previously, TD Cowen started tracking the stock with Buy rating on January 07, 2025, and set its price target to $30. On December 18, 2024, BofA Securities initiated with a Buy rating and assigned a price target of $22 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $30 on June 15, 2020. SVB Leerink initiated its recommendation with a Outperform and recommended $31 as its price target on July 29, 2019. Needham started tracking with a Buy rating for this stock on March 20, 2019, and assigned it a price target of $35. In a note dated October 30, 2018, Jefferies initiated an Buy rating and provided a target price of $30 on this stock.
KalVista Pharmaceuticals Inc [KALV] stock has fluctuated between $7.30 and $15.50 over the past year. Currently, Wall Street analysts expect the stock to reach $22.67 within the next 12 months. KalVista Pharmaceuticals Inc [NASDAQ: KALV] shares were valued at $10.35 at the most recent close of the market. An investor can expect a potential return of 119.03% based on the average KALV price forecast.
Analyzing the KALV fundamentals
Gross Profit Margin for this corporation currently stands at 0.46% with Operating Profit Margin at -142.32%, Pretax Profit Margin comes in at -129.68%, and Net Profit Margin reading is -129.68%. To continue investigating profitability, this company’s Return on Assets is posted at -0.97, Equity is -1.04 and Total Capital is -1.24. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.02 points at the first support level, and at 9.68 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.61, and for the 2nd resistance point, it is at 10.87.
Ratios To Look Out For
For context, KalVista Pharmaceuticals Inc’s Current Ratio is 6.87. On the other hand, the Quick Ratio is 6.87, and the Cash Ratio is 1.88.
Transactions by insiders
Recent insider trading involved Yea Christopher, CHIEF DEVELOPMENT OFFICER, that happened on Feb 18 ’25 when 2601.0 shares were sold. CHIEF MEDICAL OFFICER, Audhya Paul K. completed a deal on Feb 18 ’25 to sell 3125.0 shares. Meanwhile, CHIEF EXECUTIVE OFFICER Palleiko Benjamin L sold 5104.0 shares on Feb 18 ’25.
